Sulfonylureas are a class of oral medications used to lower blood sugar in people with type 2 diabetes. They work by stimulating the pancreas to release more insulin, and they’ve been in clinical use for decades. While newer drug classes have moved ahead of them in treatment guidelines, sulfonylureas remain among the most widely prescribed diabetes medications worldwide, largely because they’re effective, affordable, and available as generics.
How Sulfonylureas Lower Blood Sugar
Your pancreas contains beta cells that produce insulin. On the surface of these cells sit tiny channels that allow potassium to flow in and out, controlling whether the cell is in an “active” or “resting” state. When you eat and blood sugar rises, these channels normally close on their own, which triggers the cell to release stored insulin.
Sulfonylureas essentially force those potassium channels shut, even when blood sugar isn’t elevated enough to trigger insulin release on its own. Once the channels close, calcium floods into the beta cell, and that calcium signal causes the cell to push insulin out into the bloodstream. This is why sulfonylureas can cause low blood sugar: they stimulate insulin release regardless of whether you’ve just eaten.
Common Sulfonylurea Medications
There are two generations of sulfonylureas. The first-generation drugs are rarely used today because they require higher doses and more frequent dosing. The second-generation versions are more potent, work at lower doses, and can typically be taken once daily with the first meal of the day. The most commonly prescribed are:
- Glipizide (Glucotrol): shorter acting, often preferred for older adults
- Glimepiride (Amaryl): once daily, widely used globally
- Glyburide (Diabeta, Micronase): potent but carries a higher risk of prolonged low blood sugar
- Gliclazide (Diamicron): available outside the U.S., associated with the lowest hypoglycemia risk in its class
Despite differences in how quickly each one is absorbed or how long it stays active, the clinical outcomes during long-term use are broadly similar across the second-generation drugs. The meaningful differences show up in side effect profiles, particularly how often each one causes dangerously low blood sugar.
Where They Fit in Diabetes Treatment
Metformin is still the most common starting medication for type 2 diabetes. Sulfonylureas typically enter the picture as a second-line option when metformin alone isn’t bringing blood sugar levels to target. According to 2025 ADA guidelines, they’re a reasonable add-on for people who primarily need better glucose control and don’t have significant heart disease, heart failure, or kidney disease.
For people who do have those conditions, the guidelines now favor newer drug classes like GLP-1 receptor agonists and SGLT2 inhibitors, which offer cardiovascular and kidney protection that sulfonylureas don’t provide. The ADA’s current recommendation is direct: sulfonylurea use “should be limited or discontinued” in patients where those newer options are appropriate, since sulfonylureas don’t offer benefits beyond glucose lowering and carry added risks of hypoglycemia and weight gain.
That said, sulfonylureas are highly effective at reducing A1C, with average reductions of about 1.25% compared to placebo. For patients whose main barrier is cost or access, they remain a practical choice. They’re also used in some rare genetic forms of diabetes, including certain types of neonatal diabetes and MODY 3, where the underlying genetic defect makes the potassium channels on beta cells particularly responsive to sulfonylureas.
Side Effects and Risks
The two main concerns with sulfonylureas are low blood sugar and weight gain.
A systematic review found that about 10% of patients on any sulfonylurea experience clinically low blood sugar, while severe hypoglycemia (the kind requiring outside help) occurs in roughly 0.8% of patients. These rates vary significantly by drug. Gliclazide has the lowest risk, with only 1.4% of patients experiencing clinically low blood sugar and 0.1% experiencing a severe episode. Glyburide sits at the other end of the spectrum: it can cause prolonged low blood sugar lasting more than 24 hours because its breakdown products remain active in the body.
Weight gain is modest but consistent, typically in the range of 2 to 2.3 kilograms (about 4 to 5 pounds). This happens because the medication increases insulin output even when it’s not strictly needed, and insulin is a storage hormone that promotes fat accumulation. For people already struggling with excess weight, this can work against their broader health goals.
Kidney and Liver Considerations
Because most sulfonylureas are broken down in the liver and cleared through the kidneys, reduced function in either organ can cause the drug to accumulate and increase the risk of dangerous low blood sugar. Glyburide is contraindicated when kidney function drops below a certain threshold (roughly stage 3 kidney disease or worse). Glimepiride can be used cautiously at reduced doses in moderate kidney disease but becomes dangerous in advanced stages. If you have kidney disease, your doctor will likely choose a different medication class or adjust the dose carefully with frequent monitoring.
Drug Interactions That Raise Hypoglycemia Risk
Sulfonylureas are broken down by specific liver enzymes that many other medications also use or block. When a competing drug slows the breakdown of a sulfonylurea, it stays active in the body longer, increasing the chance of low blood sugar. Cholesterol-lowering fibrates like fenofibrate and gemfibrozil are a notable example. One study found that starting a fibrate alongside a sulfonylurea increased the rate of severe hypoglycemia, sometimes with a delayed onset over the first six months of combined use. This interaction matters because cholesterol medications are frequently prescribed alongside diabetes drugs.
Long-Term Effectiveness
One limitation of sulfonylureas is that they tend to lose effectiveness over time faster than some other diabetes medications. This is sometimes called “secondary failure.” The drug works well initially, but after months or years, blood sugar control gradually worsens despite consistent use.
The reason appears to be biological. Sulfonylureas depend entirely on functioning beta cells to work. Research on human pancreatic tissue treated with glyburide suggests the drug may accelerate the loss of beta-cell identity and increase beta-cell death. In other words, the very cells the medication relies on may wear out faster under its continuous stimulation. This contributes to the progression of type 2 diabetes and often leads to the eventual need for additional medications or insulin.
Newer sulfonylureas like glimepiride and gliclazide (sometimes called “modern” sulfonylureas) appear to have a somewhat better safety profile on this front, with lower rates of hypoglycemia and potentially less impact on beta-cell health, which is why treatment guidelines specifically recommend them over older options like glyburide when a sulfonylurea is chosen.